| Trial ID: | L7259 |
| Source ID: | NCT02829177
|
| Associated Drug: |
Allopurinol
|
| Title: |
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
| Acronym: |
MIKAL
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes|Diabetic Nephropathy
|
| Interventions: |
DRUG: Allopurinol|DRUG: Placebo
|
| Outcome Measures: |
Primary: Improved Albuminuria, Improvement of albuminuria will be evaluated by the collection of 24h urin collection with the measure of 24h albumine excretion rate and the measurements will be compared for the two treatment arm for each participant., 60 days |
|
| Sponsor/Collaborators: |
Sponsor: Peter Rossing
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2014-09
|
| Completion Date: |
2017-09-20
|
| Results First Posted: |
|
| Last Update Posted: |
2018-09-10
|
| Locations: |
Steno Diabetes Center, Gentofte, 2820, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02829177
|
